Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations - Lindholm, Evita M.; Krohn, Marit; Iadevaia, Sergio; Kristian, Alexandr; Mills, Gordon B.; Mælandsmo, Gunhild M.; Engebraaten, Olav (Clinical cancer research, 2014)
Keywords: Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - pharmacology; Animals; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - pharmacology; Antineoplastic agents; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacology; Bevacizumab; Biological and medical sciences; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cell Line, Tumor; Disease Models, Animal; Doxorubicin - administration & dosage; Doxorubicin - pharmacology; Drug Therapy, Combination; Female; Gynecology. Andrology. Obstetrics; Humans; Mammary gland diseases; Medical sciences; Mice; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Neoplasms, Basal Cell - drug therapy; Neoplasms, Basal Cell - metabolism; Neoplasms, Basal Cell - pathology; Pharmacology. Drug treatments; Phosphatidylinositol 3-Kinases - antagonists & inhibitors; Proteome; Proteomics; Signal Transduction - drug effects; TOR Serine-Threonine Kinases - antagonists & inhibitors; Treatment Outcome; Tumors; Vascular Endothelial Growth Factor Receptor-2 - metabolism; Xenograft Model Antitumor Assays; Antineoplastic agent; Drug combination; Late; Breast disease; Transplantation; Breast cancer; Monoclonal antibody; Malignant tumor; Heterotransplantation; Bevacizumab; Mammary gland diseases; Vascular endothelium growth factor; Treatment; Efficiency; Surgery; Animal; Proteomics; Graft; Early; Antiangiogenic agent; Predictive factor; Cancer